Aim: To evaluate the efficacy of intravitreal bevacizumab (IB) in the long-term control of subfoveal choroidal neovascularization (CNV) associated with angioid streaks (AS).
Methods: Patients with unilateral active CNV associated with AS were enrolled. Exclusion criteria were previous treatment for CNV and co-morbidity. Postoperative visual acuity was defined as a gain or loss of 2 or more lines of best-corrected visual acuity (BCVA).
Post-treatment CNV size was dichotomized into “increased”, if the CNV area had grown by ≥200 μm2, and “stable/reduced” if it had decreased by ≥200 μm2 or had not changed by more than 200 μm2. Patients were retreated if no further improvement or worsening was noted.
Results: Patients were 5 males and 6 females aged 33 to 58 years (mean 46.8±9.2 SD), who received a mean number of 3.5 IB treatments (±1.3; min: 2, max: 6). The mean retreatment interval was 3 months (±1.5; min: 1, max: 6). Mean follow-up duration was 23.8±2.9 months. At 20 months all patients had stable/reduced CNV size and stable/improved BCVA. Mean BCVA rose significantly from 0.28±0.2 at baseline to 0.56±0.29 at 20 months (p<0.0001).
Conclusion: IB is a promising tool for the long-term control of CNV in AS. Further studies are required to validate these findings.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.